The RNA Transcript, November 16, 2020 |
|
TODAY, Monday, November 16, 4:00–5:00 EST | U-M Center for RNA Biomedicine, RNA Innovation Seminar Series
"Splice-switching Antisense Oligonucleotides for the Treatment of Disease"
Professor, Cell Biology and Anatomy; Director, Center for Genetic Diseases, Rosalind Franklin University of Medicine and Science
|
|
CRISPR-Cas is a very diverse adaptive immune system found in bacteria and archaea. It uses a small RNA as guide to find and destroy its target. It has revolutionized the field of genome engineering once adapted as tools for use in Eukaryotes. However, only a very small fraction of CRISPR-Cas systems (<10%) have been adapted as tools so far. I am interested in exploring the diverse CRISPR-Cas systems in nature and adapting those with unique properties (e.g. CRISPR-Cas3) as tools for use in eukaryotic cells for genetic manipulation. |
|
Monday–Tuesday, November 16–17 | NIH National Cancer Institute
"Enhancers, Gene Regulation and Genome Organization"
The goal of this meeting is to critically address the wealth of new data generated by bulk and single-cell molecular, imaging and computational approaches that are increasingly revealing how the genome folds to faithfully accommodate gene expression programs and cell fate decisions. The goal is to advance an understanding of how transcriptional enhancers function, how to separate cause and effect, and to identify critical questions that will guide future directions.
|
|
Tuesday, November 17, 3:00 PM EST | U-M Department of Human Genetics, 2020 SEMINAR SERIES
ZOOM , Zoom Meeting ID: 932 5305 9153, Passcode: 859919
“Massively Parallel Approaches To Classify Variant Functional Impact In Human Disease Genes”
Jacob Kitzman, Ph.D., Assistant Professor of Human Genetics, Assistant Professor of Computational Medicine and Bioinformatic, University of Michigan
Hosted by Kenneth Kwan, Ph.D., Assistant Professor, Department of Human Genetics, Research Assistant Professor of Molecular & Behavioral Neuroscience Institute (MBNI), University of Michigan
|
|
Tuesday, November 17, 3:00 PM EST | Harvard Medical School RNA Medicine Seminar
“New biology and therapeutics from RNA structure and modifications”
Eric Miska, Ph.D., Deputy Director of the Gurdon Institute, Herchel Smith Professor of Molecular Genetics Department of Genetics, University of Cambridge, United Kingdom
|
|
Wednesday, November 18, 4:00–5:00 PM EST | U-M Department of Computational Medicine and Bioinformatics, Medical School
"Molecular and evolutionary processes generating variation in gene expression"
Patricia Wittkopp, Ph.D., Arthur F. Thurnau Professor and Sally L. Allen Collegiate Professor of Ecology & Evolutionary Biology and Molecular, Cellular & Developmental Biology, College of LSA
|
|
“Targeting telomerase RNA in degenerative diseases”
“Role of coding and non-coding genes in aggressive thyroid cancer”
Moderator: Frank Slack, Ph.D.
|
|
Registration and abstract submission for the 2020 Bay Area RNA Conference are now open: https://barc.ucsf.edu
Once you are registered, you may submit speaker/poster presentation abstracts on your profile page, ie “Submit a New Presentation.” Deadline for abstract submissions has been extended to November 21.
|
|
Our members' publications are available through Altmetric. Five queries are currently available: "RNA," "microRNA," "Transcriptome," "Translation," and "Molecule." Please make sure to have at least one of these key words in your title or abstract. Below is a recent highlight.
|
|
UAE1 inhibition mediates the unfolded protein response, DNA damage and caspase-dependent cell death in pancreatic cancer
Yajing Liu, Sahezeel Awadia, Amy Delaney, Merna Sitto, Carl G. Engelke, Heli Patel, Andrew Calcaterra, Sylvia Zelenka-Wang, Hojin Lee, Joseph Contessa, Nouri Neamati, Mats Ljungman, Theodore S. Lawrence, Meredith A. Morgan and Alnawaz Rehemtulla
Significance: The UAE1 inhibitor TAK-243, mediates activation of the unfolded protein response, accumulation of DNA breaks and apoptosis, providing a rationale for the use as a safe and efficacious anti-cancer therapeutic for PDAC.
|
|
|
|
SHARE YOUR NEWS AND COMMENTS
|
|
|
|
|
|
|
